Publications & Reference List

Publications of BioNTech RNA Pharmaceuticals:

RNA Technology & Mode of Action

Pardi N, Hogan MJ, Pelc RS, Muramatsu H, Andersen H, DeMaso CR, Dowd KA, Sutherland LL, Scearce RM, Parks R, Wagner W, Granados A, Greenhouse J, Walker M, Willis E, Yu JS, McGee CE, Sempowski GD, Mui BL, Tam YK, Huang YJ, Vanlandingham D, Holmes VM, Balachandran H, Sahu S, Lifton M, Higgs S, Hensley SE, Madden TD, Hope MJ, Karikó K, Santra S, Graham BS, Lewis MG, Pierson TC, Haynes BF, Weissman D. (2017). Nature. Zika virus protection by a single low-dose nucleoside-modified mRNA vaccination. Mar 9; 543(7644):248-251.

Poleganov, M.A., Eminli, S., Beissert, T., Herz, S., Moon, J.I., Goldmann, J., Beyer, A., Heck, R., Burkhart, I., Barea Roldan, D., et al. (2015). Efficient Reprogramming of Human Fibroblasts and Blood-Derived Endothelial Progenitor Cells Using Nonmodified RNA for Reprogramming and Immune Evasion. Hum Gene Ther. Nov; 26(11):751-766.

Kowalska, J., Wypijewska del Nogal, A., Darzynkiewicz, Z.M., Buck, J., Nicola, C., Kuhn, A.N., Lukaszewicz, M., Zuberek, J., Strenkowska, M., Ziemniak, M., et al. (2014). Synthesis, properties, and biological activity of boranophosphate analogs of the mRNA cap: versatile tools for manipulation of therapeutically relevant cap-dependent processes. Nucleic Acids Res. 42(16):10245-10264.

Sahin, U., Kariko, K., and Tureci, O. (2014). mRNA-based therapeutics–developing a new class of drugs. Nat Rev Drug Discov. Oct; 13(10):759-780.

Kreiter, S., Selmi, A., Diken, M., Koslowski, M., Britten, C.M., Huber, C., Tureci, O., and Sahin, U. (2010). Intranodal vaccination with naked antigen-encoding RNA elicits potent prophylactic and therapeutic antitumoral immunity. Cancer Res. Nov 15; 70(22):9031-9040.

Personalized Cancer Immunotherapy

Sahin U, Derhovanessian E, Miller M, Kloke BP, Simon P, Löwer M, Bukur V, Tadmor AD, Luxemburger U, Schrörs B, Omokoko T, Vormehr M, Albrecht C, Paruzynski A, Kuhn AN, Buck J, Heesch S, Schreeb KH, Müller F, Ortseifer I, Vogler I, Godehardt E, Attig S, Rae R, Breitkreuz A, Tolliver C, Suchan M, Martic G, Hohberger A, Sorn P, Diekmann J, Ciesla J, Waksmann O, Brück AK, Witt M, Zillgen M, Rothermel A, Kasemann B, Langer D, Bolte S, Diken M, Kreiter S, Nemecek R, Gebhardt C, Grabbe S, Höller C, Utikal J, Huber C, Loquai C, Türeci Ö. (2017). Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer. Nature. Jul 13; 547(7662):222-226. 

Kranz LM, Diken M, Haas H, Kreiter S, Loquai C, Reuter KC, Meng M, Fritz D, Vascotto F, Hefesha H, Grunwitz C, Vormehr M, Hüsemann Y, Selmi A, Kuhn AN, Buck J, Derhovanessian E, Rae R, Attig S, Diekmann J, Jabulowsky RA, Heesch S, Hassel J, Langguth P, Grabbe S, Huber C, Türeci Ö, Sahin U. (2016). Systemic RNA delivery to dendritic cells exploits antiviral defence for cancer immunotherapy. Nature. Jun 1; 534(7607):396-401.

Kreiter, S., Vormehr, M., van de Roemer, N., Diken, M., Lower, M., Diekmann, J., Boegel, S., Schrors, B., Vascotto, F., Castle, J.C., et al. (2015). Mutant MHC class II epitopes drive therapeutic immune responses to cancer. Nature. Apr 30; 520(7549):692-696.

Castle, J.C., Loewer, M., Boegel, S., de Graaf, J., Bender, C., Tadmor, A.D., Boisguerin, V., Bukur, T., Sorn, P., Paret, C., et al. (2014). Immunomic, genomic and transcriptomic characterization of CT26 colorectal carcinoma. BMC Genomics. 15:190.

Castle, J.C., Kreiter, S., Diekmann, J., Lower, M., van de Roemer, N., de Graaf, J., Selmi, A., Diken, M., Boegel, S., Paret, C., et al. (2012). Exploiting the mutanome for tumor vaccination. Cancer Res. Mar 1; 72(5):1081-1091.

Publications of BioNTech Cell & Gene Therapies:

Publications of BioNTech Protein Therapeutics: